Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm neoadjuvant PLD + cyclophosphamide + trastuzumab + pertuzumab followed by taxanes + trastuzumab + pertuzumab in HER2-positive breast cancer
ChiCTR1900028433Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, cyclophosphamide, trastuzumab and pertuzumab in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Pathological complete response rate. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900028433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028433.